InspireMD (NSPR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NSPR InspireMD

Watchlist

2.880
-0.050-1.71%

Trading Jul 25 10:40 ET

72.73MMarket Cap-5760P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

InspireMD Brings in $17.9M to Support Stent Trial
MassDeviceJul 1 14:36 ET
InspireMD Secures Funds to Expand Healthcare Innovations
TipRanksJul 1 07:34 ET
Express News | InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
ReutersJul 1 07:00 ET
Express News | InspireMD: Files Prospectus Supplement to Offer, Sell Common Stock of up to $17 Mln From Time to Time Under Equity Distribution Deal With Piper Sandler
ReutersMay 31 17:22 ET
InspireMD's CGuard Stent Shows Promise in C-GUARDIANS Trial
TipRanksMay 28 11:02 ET
Express News | InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 A.m. EDT
BenzingaMay 28 08:56 ET

Comments

$InspireMD(NSPR.US)$ the mesh stint will become FDA approved. When is the question.

$InspireMD(NSPR.US)$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

$InspireMD(NSPR.US)$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved

$InspireMD(NSPR.US)$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53

Mixed bag, not bad though!

$InspireMD(NSPR.US)$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

Top Gainers Yesterday

Top Gainers Yesterday